The authors developed CAR T cells against multiple myeloma using a binder to targeting transmembrane activator and CAML interactor in mono and dual-specific formats with anti-B cell maturation antigen (BCMA).
[Nature Communications]
Home Newsletters Cell Therapy News Anti-TACI Single and Dual-Targeting CAR T Cells Overcome BCMA Antigen Loss in...
